FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328049399> ?p ?o ?g. }

• W4328049399 endingPage "918" @default.
• W4328049399 startingPage "918" @default.
• W4328049399 abstract "Chronic lymphocytic leukemia (CLL), defined by a minimum of 5 × 109/L monoclonal B cells in the blood, affects more than 200 000 people and is associated with approximately 4410 deaths in the US annually. CLL is associated with an immunocompromised state and an increased rate of complications from infections.At the time of diagnosis, the median age of patients with CLL is 70 years, and an estimated 95% of patients have at least 1 medical comorbidity. Approximately 70% to 80% of patients with CLL are asymptomatic at the time of diagnosis, and one-third will never require treatment for CLL. Prognostic models have been developed to estimate the time to first treatment and the overall survival, but for patients who are asymptomatic, irrespective of disease risk category, clinical observation is the standard of care. Patients with symptomatic disease who have bulky or progressive lymphadenopathy or hepatosplenomegaly and those with a low neutrophil count, anemia, or thrombocytopenia and/or symptoms of fever, drenching night sweats, and weight loss (B symptoms) should be offered treatment. For these patients, first-line treatment consists of a regimen containing either a covalent Bruton tyrosine kinase (BTK) inhibitor (acalabrutinib, zanubrutinib, or ibrutinib) or a B-cell leukemia/lymphoma 2 (BCL2) inhibitor (venetoclax). There is no evidence that starting either class before the other improves outcomes. The covalent BTK inhibitors are typically used indefinitely. Survival rates are approximately 88% at 4 years for acalabrutinib, 94% at 2 years for zanubrutinib, and 78% at 7 years for ibrutinib. Venetoclax is prescribed in combination with obinutuzumab, a monoclonal anti-CD20 antibody, in first-line treatment for 1 year (overall survival, 82% at 5-year follow-up). A noncovalent BTK inhibitor, pitobrutinib, has shown an overall response rate of more than 70% after failure of covalent BTK inhibitors and venetoclax. Phosphoinositide 3'-kinase (PI3K) inhibitors (idelalisib and duvelisib) can be prescribed for disease that progresses with BTK inhibitors and venetoclax, but patients require close monitoring for adverse events such as autoimmune conditions and infections. In patients with multiple relapses, chimeric antigen receptor T-cell (CAR-T) therapy with lisocabtagene maraleucel was associated with a 45% complete response rate. The only potential cure for CLL is allogeneic hematopoietic cell transplant, which remains an option after use of targeted agents.More than 200 000 people in the US are living with a CLL diagnosis, and CLL causes approximately 4410 deaths each year in the US. Approximately two-thirds of patients eventually need treatment. Highly effective novel targeted agents include BTK inhibitors such as acalabrutinib, zanubrutinib, ibrutinib, and pirtobrutinib or BCL2 inhibitors such as venetoclax." @default.
• W4328049399 created "2023-03-22" @default.
• W4328049399 creator A5007310385 @default.
• W4328049399 date "2023-03-21" @default.
• W4328049399 modified "2023-10-06" @default.
• W4328049399 title "Diagnosis and Treatment of Chronic Lymphocytic Leukemia" @default.
• W4328049399 cites W154103547 @default.
• W4328049399 cites W1965851569 @default.
• W4328049399 cites W2025707347 @default.
• W4328049399 cites W2055886080 @default.
• W4328049399 cites W2061445038 @default.
• W4328049399 cites W2063204645 @default.
• W4328049399 cites W2066357502 @default.
• W4328049399 cites W2066564017 @default.
• W4328049399 cites W2067064694 @default.
• W4328049399 cites W2070487917 @default.
• W4328049399 cites W2094504646 @default.
• W4328049399 cites W2108206643 @default.
• W4328049399 cites W2113254351 @default.
• W4328049399 cites W2136683961 @default.
• W4328049399 cites W2140499692 @default.
• W4328049399 cites W2153230055 @default.
• W4328049399 cites W2233614027 @default.
• W4328049399 cites W2234243759 @default.
• W4328049399 cites W2318933236 @default.
• W4328049399 cites W2337485820 @default.
• W4328049399 cites W2396328865 @default.
• W4328049399 cites W2469555883 @default.
• W4328049399 cites W2589157782 @default.
• W4328049399 cites W2589238872 @default.
• W4328049399 cites W2773047201 @default.
• W4328049399 cites W2787916641 @default.
• W4328049399 cites W2790385276 @default.
• W4328049399 cites W2792666902 @default.
• W4328049399 cites W2800186514 @default.
• W4328049399 cites W2895287765 @default.
• W4328049399 cites W2902484351 @default.
• W4328049399 cites W2902706178 @default.
• W4328049399 cites W2936399310 @default.
• W4328049399 cites W2945468305 @default.
• W4328049399 cites W2950737717 @default.
• W4328049399 cites W2954311907 @default.
• W4328049399 cites W2966190920 @default.
• W4328049399 cites W2973195462 @default.
• W4328049399 cites W3003468352 @default.
• W4328049399 cites W3008994472 @default.
• W4328049399 cites W3009351592 @default.
• W4328049399 cites W3012414877 @default.
• W4328049399 cites W3014127006 @default.
• W4328049399 cites W3029637120 @default.
• W4328049399 cites W3038687742 @default.
• W4328049399 cites W3045571650 @default.
• W4328049399 cites W3080675765 @default.
• W4328049399 cites W3082899459 @default.
• W4328049399 cites W3092620211 @default.
• W4328049399 cites W3092937247 @default.
• W4328049399 cites W3134524629 @default.
• W4328049399 cites W3155803123 @default.
• W4328049399 cites W3171959109 @default.
• W4328049399 cites W3185756680 @default.
• W4328049399 cites W3210008249 @default.
• W4328049399 cites W3214546710 @default.
• W4328049399 cites W4200435825 @default.
• W4328049399 cites W4200464662 @default.
• W4328049399 cites W4205825534 @default.
• W4328049399 cites W4205969691 @default.
• W4328049399 cites W4210589143 @default.
• W4328049399 cites W4223904810 @default.
• W4328049399 cites W4224138250 @default.
• W4328049399 cites W4224260079 @default.
• W4328049399 cites W4225906349 @default.
• W4328049399 cites W4226237761 @default.
• W4328049399 cites W4229368832 @default.
• W4328049399 cites W4234057679 @default.
• W4328049399 cites W4237354326 @default.
• W4328049399 cites W4240717803 @default.
• W4328049399 cites W4280503361 @default.
• W4328049399 cites W4281385697 @default.
• W4328049399 cites W4283029355 @default.
• W4328049399 cites W4283381496 @default.
• W4328049399 cites W4283388585 @default.
• W4328049399 cites W4284883545 @default.
• W4328049399 cites W4286235110 @default.
• W4328049399 cites W4289524022 @default.
• W4328049399 cites W4294991153 @default.
• W4328049399 cites W4296711793 @default.
• W4328049399 cites W4309346784 @default.
• W4328049399 cites W4311293040 @default.
• W4328049399 cites W4312210443 @default.
• W4328049399 cites W4317987797 @default.
• W4328049399 doi "https://doi.org/10.1001/jama.2023.1946" @default.
• W4328049399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36943212" @default.
• W4328049399 hasPublicationYear "2023" @default.
• W4328049399 type Work @default.
• W4328049399 citedByCount "12" @default.
• W4328049399 countsByYear W43280493992023 @default.
• W4328049399 crossrefType "journal-article" @default.
• W4328049399 hasAuthorship W4328049399A5007310385 @default.

• next